Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
22 January 2024 | Story Leonie Bolleurs | Photo Born2shoot
Dr Tommie van Zyl, Prof Philippe Burger and Prof Francis Petersen
At the launch of NovaLogix, a company co-owned by the UFS and ZZ2, were, from the left, Dr Tommie van Zyl, CEO of the ZZ2 Group, and Prof Philippe Burger, Dean of the Faculty of Economic and Management Sciences, and Prof Francis Petersen, Vice-Chancellor and Principal.

The University of the Free State (UFS) recently (17 January 2024) launched NovaLogix in collaboration with ZZ2, a well-known South African fresh produce company.

This new company, co-owned by the university and ZZ2, aims to develop and produce a probiotic used in the production of fresh produce to enhance plant health and growth. Projects include a focus on improved production techniques, product registration, commercialisation, and improved recipes.

Members of the university’s management structures were present at the formal launch of NovaLogix – which took place on the UFS Bloemfontein Campus – including the Vice-Chancellor and Principal, Prof Francis Petersen; the Deputy Vice-Chancellor: Research and Internationalisation, Prof Vasu Reddy; and the Senior Director of the Directorate Research Development, Dr Glen Taylor. The deans of the two faculties that will be mainly involved in this partnership were also present, namely Prof Paul Oberholster, the Dean of the Faculty of Natural and Agricultural Sciences, and Prof Philippe Burger, the Dean of the Faculty of Economic and Management Sciences.

Among the attendees representing ZZ2 were Dr Tommie van Zyl, the Chief Executive Officer of the ZZ2 Group, Piet Prinsloo, Executive Manager at ZZ2, as well as Wiam Haddad, the new CEO of NovaLogix.

Co-creation and more sustainable outcomes

In his welcoming remarks, Prof Petersen stated that this event marks the culmination of a five-year journey that began in 2019 when he, Prof Burger, and Prof Danie Vermeulen, former Dean of the Faculty of Natural and Agricultural Sciences, first visited ZZ2 to initiate closer collaboration and cooperation.

He is of the opinion that the relationship with ZZ2 is ideally suited to assist the university in realising the core values of Vision 130, the university’s strategic intent to reposition the institution as one of the leading universities in South Africa by 2034.

The knowledge, experience, and expertise that ZZ2 brings to the partnership, complement the exciting and impactful research done by the university’s academics across a range of disciplines. - Prof Francis Petersen

Prof Petersen said that the UFS values partnerships with the private sector, and he considers ZZ2 to be a knowledge partner with co-creation as a key component in this collaboration.

“Working together on a challenge makes the solution more sustainable. I believe that innovation and this co-creation approach will generate outcomes that transform the agricultural sector and impart knowledge to the next generation,” he stated.

“The knowledge, experience, and expertise that ZZ2 brings to the partnership complement the exciting and impactful research conducted by the university’s academics across a range of disciplines. I am looking forward to a partnership that will grow from strength to strength,” concluded Prof Petersen.

Breakthrough developments in the pipeline

According to Dr Van Zyl, ZZ2 would like to continue building a future with the university based on a symbiotic relationship. “We want to ensure that our strengths as an organisation are put to good use,” he said, expressing a strong conviction that there will be breakthrough developments with this initiative.

This work will align with ZZ2’s ‘Work with nature’ journey that began more than two decades ago, steering away from conventional, industrial agriculture towards a system that aims to farm in harmony with nature. “It is important that we nurture nature while using her resources,” he said.

He is excited to work with the university, exploring improved techniques and technologies to find more effective ways towards a sustainable future. “Knowledge partners are important in this journey,” he stated.

Building on existing collaborations

In September 2022, the university entered into a collaboration agreement with ZZ2. The partnership between the two entities included the establishment of FreeFarm Innovation, a company that in turn has a holding in NovaLogix and is designed to leverage the strengths, capabilities, skills, and resources of both parties. Part of the operations of FreeFarm Innovation included opportunities for research, commercialisation, and the enhancement of agricultural products. This has come into effect in projects on, for example, business operations, agricultural sustainability, and innovative approaches to growing fruit and vegetables, to name but a few.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept